Anti-FOXP3 antibody [236A/E7] (Ab20034)
IPEX, JM2, FOXP3, Forkhead box protein P3, Scurfin
详细信息
特异性
The epitope recognized by FOXP3 antibody [236A/E7] (ab20034) is between amino acids 105-236. FOXP3 antibody [236A/E7] (ab20034) is expected to detect full length FOXP3 as well as both cleaved forms.
背景信息
Anti-FOXP3 antibody [236A/E7] (ab20034) is a mouse recombinant monoclonal antibody and is validated for use in IHC-P, WB and mIHC. Anti-FOXP3 antibody [236A/E7] (ab20034) was first used in a scientific publication in 2005 and has been cited over 593 times in peer reviewed journals. It's performance in IHC in human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-FOXP3 antibody [236A/E7] (ab20034) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-FOXP3 antibody [236A/E7] (ab20034) has 37 independent reviews from customers. Anti-FOXP3 antibody [236A/E7] (ab20034) specifically detects FOXP3 (UniProt ID: Q9BZS1; Molecular weight: 48kDa) and is sold in a convenient trial size to enable initial testing (10ug, 20 µg) and larger sizes for subsequent scaling up experiments (100 µg and 1 mg). Conjugation-ready, carrier free format available for antibody clone 236A/E7 - ab96048. FOXP3 is essential for the development and function of regulatory T cells (Tregs), which help maintain immune tolerance. In cancer, FOXP3-expressing Tregs suppress anti-tumor immune responses, aiding tumor growth and progression.
文献引用 (514)
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.
Linavonkibart 和 pembrolizumab 治疗免疫检查点阻断耐药的晚期实体瘤：一项 1 期试验。
Integrative Multi-Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer.
整合多组学分析揭示了预测胃癌联合免疫疗法反应的免疫表型。
Deletion of STIM1 in Treg cells protects against lung fibrosis and associated cardiovascular complications in a pre-clinical mouse model.
在临床前小鼠模型中，Treg 细胞中 STIM1 的缺失可防止肺纤维化及相关的心血管并发症。
Hyodeoxycholic acid attenuates atherosclerosis by antagonizing FXR and modulating the PD-1/mTORC1 signaling axis.
脱氧胆酸通过拮抗 FXR 和调节 PD-1/mTORC1 信号轴来减轻动脉粥样硬化。
Enhancing gastric cancer immunotherapy: Insights from multi-omics analysis and innovations in photodynamic-chemotherapy nanoplatforms.
增强胃癌免疫疗法：来自多组学分析和光动力化学疗法纳米平台创新的见解。
A phase II study of docetaxel and pembrolizumab plus Interleukin-12 gene therapy in non-metastatic, anthracycline-refractory triple negative breast cancer (INTEGRAL).
一项针对非转移性、蒽环类药物难治性三阴性乳腺癌的多西他赛和帕博利珠单抗联合白细胞介素-12基因疗法的II期研究（INTEGRAL）。
Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer.
西妥昔单抗和纳武利尤单抗治疗复发/转移性头颈癌的 II 期临床试验的长期生存率和分子生物标志物评估。
Regulatory T cells attenuate astrogliosis via IL-10/STAT3/PKC/vimentin signaling and promote neurological recovery after spinal cord injury.
调节性 T 细胞通过 IL-10/STAT3/PKC/波形蛋白信号传导减弱星形胶质增生，并促进脊髓损伤后的神经功能恢复。
High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer.
PD-L1 高表达是 III 期胃癌的不良预后因素，但不是 II 期胃癌的不良预后因素。
Multi-omics profiling reveals that Scissor(+) epithelial cells regulate intrahepatic metastasis of HCC via remodeling the metastatic microenvironment.
多组学分析表明，Scissor(+)上皮细胞通过重塑转移微环境来调节HCC的肝内转移。
- 1
- 2
- 3
- 4
- 5
- 6
- 52